Bivalent AMPA Receptor Modulators for Cognitive Deficits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive deficits associated with glutamatergic hypofunction, such as schizophrenia and Alzheimer's disease, lack effective therapeutic options that can enhance excitatory neurotransmission without risking excitotoxicity.
Innovation Solution
Development of bivalent AMPAR positive allosteric modulators (PAMs) that target specific binding domains on AMPA receptors, enhancing glutamatergic neurotransmission while preventing neuroapoptosis and cognitive impairment, using asymmetric ligands with indole, azaindole, pyridine, or benzothiazole scaffolds to improve potency and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If direct activation of glutamate receptors by agonists is used to correct glutamatergic hypofunction, then neurotransmission is enhanced, but the risk of excitotoxicity and neuronal damage increases
Solution Approach 1:
The patent employs positive allosteric modulators (PAMs) as intermediary molecules that indirectly enhance AMPA receptor function without directly activating the receptor. These PAMs bind to allosteric sites and increase receptor sensitivity to endogenous glutamate, thereby enhancing neurotransmission while avoiding the excitotoxicity associated with direct agonist activation.
Solution Approach 2:
The invention utilizes bivalent molecular structures with specific pharmacokinetic parameters (molecular weight, lipophilicity, polar surface area) optimized to achieve selective binding to AMPA receptor allosteric sites. This parameter optimization allows the compounds to enhance receptor function through allosteric modulation rather than direct activation, resolving the contradiction between efficacy and safety.
2Reliability
If bivalent AMPAR PAMs with complex structures are designed to improve potency and specificity, then therapeutic efficacy is enhanced, but drug-likeness and brain penetration capability may be compromised
Solution Approach 1:
The patent employs asymmetric bivalent molecular structures where two distinct binding domains are attached to a central scaffold at non-equivalent positions. This asymmetry enables selective interaction with specific AMPA receptor subunit combinations (e.g., GluA1-GluA3 heterodimers), enhancing potency and specificity while maintaining manageable molecular complexity through strategic placement of functional groups.
Solution Approach 2:
The invention systematically optimizes key pharmacokinetic parameters including molecular weight (250-500 Da), lipophilicity (logP 2-4), and polar surface area (60-120 Ų) to balance potency, specificity, and drug-likeness. These parameter constraints ensure that despite the bivalent structure, the compounds maintain adequate oral bioavailability and blood-brain barrier penetration.
Data Source
AI summary
Embodiments of the invention are directed to compounds that are positive allosteric modulators of AMPA receptors.